Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBVX.L Regulatory News (BVX)

  • There is currently no data for BVX

Holding(s) in Company

16 Aug 2023 18:00

RNS Number : 5566J
BiVictriX Therapeutics PLC
16 August 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

BIVICTRIX THERAPEUTICS PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

X

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

CANACCORD GENUITY GROUP INC

City and country of registered office (if applicable)

VANCOUVER, CANADA

4. Full name of shareholder(s) (if different from 3.)v

Name

DISCRETIONARY CLIENTS

City and country of registered office (if applicable)

As above

5. Date on which the threshold was crossed or reachedvi:

10 AUGUST 2023

6. Date on which issuer notified (DD/MM/YYYY):

11 AUGUST 2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

10.9989

10.9989

9,076,924

Position of previous notification (if

applicable)

9.0751

9.0751

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BNXH3K91

9,076,924

10.9989

SUBTOTAL 8. A

9,076,924

10.9989

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

 

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

Canaccord Genuity Group Inc.

10.9989

10.9989

 

Canaccord Genuity Wealth Group Holdings Limited

10.9989

10.9989

 

Canaccord Genuity Wealth Group Holdings (Jersey) Limited

10.9989

10.9989

 

Canaccord Genuity Wealth Group Limited

10.9989

10.9989

 

Canaccord Genuity Asset Management Limited (formerly Hargreave Hale Limited)

10.9989

10.9989

 

 

 

10. In case of proxy voting, please identify:

 

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

 

11. Additional informationxvi

 

The change in the percentage of shares held was due entirely to participation in the placing by Bivictrix Therapeutics plc, the shares from which were admitted to AIM on 10th August 2023.

 

 

 

 

Place of completion

BLACKPOOL, ENGLAND

Date of completion

11 AUGUST 2023

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUNONRORUWAAR
12
Date   Source Headline
11th Sep 20247:00 amRNSCancellation - BiVictriX Therapeutics plc
10th Sep 202411:04 amRNSHolding(s) in Company
10th Sep 20247:00 amRNSLast Day of Dealings
9th Sep 20247:00 amRNSPositive In Vivo Data from BVX002 Programme
2nd Sep 20245:04 pmRNSHolding(s) in Company
2nd Sep 20248:50 amRNSDirector Dealing
29th Aug 20245:05 pmRNSResult of General Meeting
28th Aug 202410:14 amRNSHolding(s) in Company
28th Aug 202410:12 amRNSHolding(s) in Company
19th Aug 20247:00 amRNSTR-1: Notification of major holdings
13th Aug 20247:00 amRNSGrant of Options
12th Aug 20247:00 amRNSProposed Voluntary Delisting
1st Aug 20247:00 amRNSInterim Results
24th Jul 20245:00 pmRNSResult of Annual General Meeting
26th Jun 20247:00 amRNSPublication of 2023 Annual Report & Notice of AGM
13th Jun 20247:00 amRNSCompelling Safety Profile of BVX001
6th Jun 20247:00 amRNSInnovate UK Grant Award to Accelerate ADC Pipeline
31st May 20248:44 amRNSBiVictriX – Full Year Results 2023
17th Apr 20247:00 amRNSOrphan Drug Designation & FDA INTERACT Meeting
28th Mar 20247:00 amRNSGrant of Options – PDMR/Director Dealings
4th Jan 202412:30 pmRNSHolding(s) in Company
4th Jan 202412:30 pmRNSHolding(s) in Company
4th Jan 20247:00 amRNSBiVictriX Hosts Inaugural Roundtable Discussion
5th Dec 202311:08 amRNSBoard Change
30th Nov 20237:00 amRNSPipeline update on BVX002
22nd Nov 20235:14 pmRNSHolding(s) in Company
15th Nov 20237:00 amRNSPatent Granted in Japan
12th Oct 20237:00 amRNSExtended Survival Rates Reported with BVX001
3rd Oct 20237:00 amRNSAppointment of Adrian Howd as CFO and CBO
19th Sep 20237:00 amRNSInterim Results
31st Aug 20237:00 amRNSTotal Voting Rights
23rd Aug 20237:00 amRNSUS Patent Granted
17th Aug 20237:00 amRNSHolding(s) in Company
16th Aug 20236:00 pmRNSHolding(s) in Company
11th Aug 20234:17 pmRNSHolding(s) in Company
8th Aug 20235:18 pmRNSResult of General Meeting
19th Jul 20236:16 pmRNSResult of Conditional Fundraise
19th Jul 202312:31 pmRNSProposed Fundraise in excess of £2 million
17th Jul 20237:00 amRNSPositive final data in preclinical efficacy study
19th Jun 20237:00 amRNSPositive interim data
6th Jun 20237:00 amRNSBiVictriX nominates clinical candidate for BVX001
4th May 20234:36 pmRNSResult of Annual General Meeting
31st Mar 20237:00 amRNSPublication of Annual Report and Notice of AGM
30th Mar 20237:00 amRNSBiVictriX Full Year Results
1st Mar 20237:01 amRNSAppointment of Alex Hughes as CFO
31st Jan 20237:08 amRNSBiVictriX reports positive BVX001 preclinical data
24th Jan 20234:21 pmRNSHolding(s) in Company
19th Jan 202311:00 amRNSHolding(s) in Company
19th Jan 20237:00 amRNSHolding(s) in Company
16th Jan 20234:32 pmRNSHolding(s) in Company
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.